Clinical Trials Logo

HER2 Gene Mutation clinical trials

View clinical trials related to HER2 Gene Mutation.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06178445 Not yet recruiting - Clinical trials for Biliary Tract Cancer

Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract Cancer

TRAP-BTC
Start date: January 2024
Phase: Phase 2
Study type: Interventional

This is a multicenter, single arm, prospective, open-label phase II trial investigating the clinical activity triplet regimen consisting of a combination of chemotherapy (gemcitabine/cisplatin) + trastuzumab + pembrolizumab as first-line treatment for cholangiocarcinoma and gallbladder cancer patients. Patients suffering from previously untreated HER2 (human epidermal growth factor receptor 2) positive, unresectable cholangiocarcinoma and gallbladder cancer will be included in the study and are scheduled to receive triplet regimen consisting of a combination of pembrolizumab, trastuzumab and gemcitabine/cisplatin (GemCis).

NCT ID: NCT04179656 Not yet recruiting - Solid Tumor Clinical Trials

The Basket Study of Pyrotinib Maleate for HER2-Postive Solid Tumor

Start date: December 2019
Phase: Phase 2
Study type: Interventional

This is an open-label, Phase 2 study exploring the efficacy and safety of 马来酸Pyrotinib Maleate Tablets in patients with solid tumors with activating(harmful) HER2 mutations or with HER2 gene amplification or immunohistochemical staining (IHC) assay showing HER2 is 3+ and / or fluorescence in situ hybridization (FISH) positive.

NCT ID: NCT03743350 Not yet recruiting - Clinical trials for Non Small Cell Lung Cancer

NSCLC Exon 20 or HER2-activating Mutations

RAIN
Start date: February 2019
Phase: Phase 2
Study type: Interventional

Phase 2, Open Label, single treatment